AI-based slide review system introduced at Otsuka Pharmaceutical Co., Ltd.

2023.02.27 Press release

--To the press -

AI-based slide review system introduced at Otsuka Pharmaceutical Co., Ltd.

Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Growth)

 FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter: FRONTEO) is a slide review AI at the Medical Affairs Department of Otsuka Pharmaceutical Co., Ltd. (Location: Tokyo, hereinafter: Otsuka Pharmaceutical). We would like to inform you that the system has been installed.

 This system uses FRONTEO's in-house developed natural language analysis AI to review presentation slides used at lectures held by pharmaceutical companies for medical professionals.Various rules have been established for such slides from the perspective of providing information on the proper use of ethical drugs, and pharmaceutical companies are required to comply with them.This rule is becoming stricter year by year, and with the increase in online seminars hosted by pharmaceutical companies due to the spread of new coronavirus infections, etc., the burden of slide review work at pharmaceutical companies is increasing.

 In this system, AI analyzes the information written on the slides and issues an alarm for slides containing preset points to be observed from the perspective of proper use, supporting reliable verification and appropriate document creation.

 FRONTEO will contribute to the efficiency and quality improvement of pharmaceutical companies' operations through research, development and provision of advanced systems using in-house developed AI, which has strengths in natural language processing.

 The impact of this matter alone on the business results for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.

FRONTEO is a data analysis company that uses the in-house developed AI engines KIBIT and Concept Encoder, Looca Cross specialized in natural language processing to extract meaningful and significant information from a large amount of textual data and support companies' business. Since its inception in August 2003, we have been working globally with Japan, the United States, Korea, and Taiwan, mainly in the Legaltech business, such as e-discovery (electronic evidence disclosure) and digital forensic surveys, which support company international lawsuits. Based on AI technology developed in this project, we have expanded our business fields to life science, business intelligence, and economic security since 8, and have used AI to transform textual data into knowledge, thus contributing to the resolution of various companies' issues, including support for drug discovery, support for dementia diagnostics, and support for financial, human resources, and business. Listed on TSE Mothers (currently TSE Growth) on June 2014, 2007. In January 6, the company obtained a license to manufacture and sell Class I medical devices (license number: 26B2021X1), and in September of the same year, the company submitted a notification to sell controlled medical devices (notification number: 13MinatoMiSeikikiDai1). Capital: ¥10350 (as of March 9, 3).

* FRONTEO, KIBIT, conceptencoder, and Looca Cross are registered trademarks of FRONTEO in Japan.


<Contact for inquiries from the press>
PR Department, FRONTEO, Inc.

<Contact for inquiries regarding the life science AI business>
Life Science AI Business Department, FRONTEO, Inc.

ja 日本語
Machine Translation by Google. : close x